



Call for 2026 Scientific Abstracts and Case Study Reports

General Information

All abstract submissions are due by **11:59 p.m. PT on Friday, November 14, 2025**.

Accepted abstracts are required to be presented **in person** at the 2026 ACMG Annual Clinical Genetics Meeting in Baltimore, MD. Presenters unable to travel may designate a co-author to serve as the presenter.

Publication: All accepted abstracts will be published in *Genetics in Medicine Open*.

Submission Types

Authors must select one of the following during submission. The choice is final and cannot be changed once the review committee has made its decision.

1. **Scientific Abstracts** – Original scientific research presented as a **Platform** or **Poster**.
2. **Case Study Reports** – Unique or rare case reports, presented as **Posters only**.

Abstract Submission Fee (New)

Beginning in 2026, ACMG will require a **non-refundable abstract submission fee** for nonmembers. This fee must be paid at the time of submission for an abstract to be considered for review.

Fee Structure

- **ACMG Members: No Fee**
 - Important: Log in using your ACMG membership account to ensure you are recognized as a member and not charged in error.
- **Nonmembers: \$75**
- **NIH Employees and Applicants from [Resource-Limited countries](#):** You may request an exception by following the instructions below:
 - Complete all of the required information to submit your abstract, except the payment. Save your draft abstract in the system.
 - Email education@acmg.net with “Abstract Fee Review” in the subject line and the title of your abstract in the body of the email. Requests are due by **Wednesday, November 12th**.
 - Submissions will be reviewed on a case-by-case basis.
 - Once you receive a response from education@acmg.net, you may return to the system to submit your abstract.

Payment Information

- The abstract submission fee is collected through the online submission system at the time the **Submit** button is clicked. Draft abstracts may be created and saved in the system, but they will not be considered for review until final submission and payment are completed.
- Fees are **non-refundable**, regardless of acceptance status.
- Payment must be made via credit card through the secure online submission system. No other payment methods will be accepted.

Important Dates

- **Wednesday, October 1, 2025** – Call for Abstracts Housing and Registration Opens
- **Friday, November 14, 2025** – Abstract Submission Deadline
- **November 18 – December 5, 2025** – Abstract Review Process
- **Wednesday, December 10, 2025** – Abstract Acceptance/Rejection Notices Sent
- **Wednesday, December 17, 2025** – Early Bird Registration Deadline
- **Monday, January 5, 2026** – Platform Presenters Complete Participation Forms in Presenter Portal
- **February 4, 2026 - Advance Registration Deadline**
- **Friday, February 6, 2026** – Abstract Withdrawal Deadline
- **Friday, February 27, 2026** – ePosters with Audio Tour
- **February 2 – March 6, 2026** – Platform Sessions Slide Review and Peer Review Process
- **February 27, 2026** - Platform Sessions PowerPoint Presentations Due
- **Wednesday, March 11, 2026, 5:00 p.m. ET** – Poster Embargo Lifts
- **March 10–14, 2026** – See you in Baltimore, MD

I. Scientific Abstract Submission (Eligible for Abstract Awards)

Overview

Scientific abstracts are concise summaries of original unpublished research. Fifty-two (52) of the highest-rated abstracts will be selected for **Platform Presentations**; all others will be presented as **Posters**.

In addition to traditional printed posters, authors must upload an **electronic poster** for online viewing.

Submission Options

1. **Scientific Platform with Reflex to Poster** – Considered first for platform; if not accepted, may be accepted as poster.
2. **Scientific Poster Only** – Will not be considered for platform presentation.
3. **Scientific Platform Only** – Will not be considered for poster presentation.

Scientific Abstract Structure

- **Introduction** – Context and research question.
- **Methods** – Study design and techniques used.
- **Results** – Key findings presented clearly.
- **Conclusions** – Interpretation, significance, and implications.

Presentation Formats

- **Platform Presentations** – 13-minute talk + 2 minutes Q&A (total 15 minutes). Four of the highest-rated will be featured in a **special plenary session**. Pre-recorded or remote presentations are **not allowed**.
- **Poster Sessions** – Traditional printed posters plus mandatory electronic upload.

II. Case Study Report Submission (Not eligible for an abstract award)

Overview

Case Study Reports highlight unique or rare cases, outlining the patient's symptoms, diagnosis, treatment, and follow-up.

- **Three or more cases** should be submitted as a scientific abstract.
- Case Study Reports are **not eligible** for platform presentation or awards.

Submission Options

1. Case Study Report – Poster Presentation Only

Abstract Structure

- **Introduction** – Emphasize significance or rarity.
- **Case Presentation** – Patient's symptoms, history, and relevant factors.
- **Diagnostic Workup** – Tests, unusual findings.
- **Treatment and Management** – Care provided, including experimental therapies.
- **Outcome and Follow-up** – Patient's response and long-term outcomes.
- **Discussion** – Comparison with literature and clinical significance.
- **Conclusion** – Key insights and future directions.

Submission Guidelines

- Abstracts must be structured and are allotted 600 words.
- Use italic type where necessary. Bold and underline formation are not allowed.
- Text may be in multiple paragraphs.
- Special Greek and mathematical symbols are available in a character map within the submission system.
- Use numerals to indicate numbers, except when beginning sentences.
- Do not include figures, diagrams, images, references, or tables.
- Proofreading is the responsibility of the author.

Topic Categories

1. Basic Research
2. Cancer
3. Clinical - Adult
4. Clinical - Adult & Pediatric
5. Clinical - Pediatric
6. Clinical Genetics
7. Ethical, Legal, Social Issues (ELSI)
8. General Education
9. Genetic Counseling
10. Genomic Medicine
11. Healthcare Inequities and Health Disparities
12. Health Services and Implementation
13. Laboratory Genetics
14. Metabolic Genetics
15. Newborn Screening
16. Population Genetics
17. Prenatal Genetics
18. Public Health Genetics
19. Therapies for Genetic Conditions

Key Topic Focus

1. Biochemical/Metabolic and Therapeutics
2. Cancer Genetics and Therapeutics

3. Clinical Genetics and Therapeutics
4. Health Services and Implementation
5. Laboratory Genetics and Genomics
6. Prenatal Genetics
7. Education and Research Strategies
8. Ethical, Legal, Social Issues (ELSI), Public Health and Policy

Responsibilities of the Submitter/Presenting Author

- **The submitting author must be the first author and** is responsible for the following:
 - The first author serves as point of contact for all correspondence regarding the abstract.
 - Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
 - Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ACMG.
 - Ensuring that all authors approve of submitting this work for presentation and publication.
 - Abiding by all formatting
- The author(s) agree(s) to materially confine the presentation to information in the abstract, if accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session.
- The presenting author will be available to present the abstract if selected for the program. The author(s) will immediately notify ACMG if the first author is not the presenting author.
- The **presenting author** must be one of the co-authors listed on the submitted abstract. The presenting author must be confirmed prior to abstract submission.
- An individual may be first author (i.e., presenting author) of more than one abstract. If the first author should have multiple accepted Posters and has a conflict with the Poster presentation schedule, then it is acceptable to designate one of the co- authors to present one of the Posters.

Abstract Review and Selection Process

- Scientific abstracts evaluated on **scientific merit, clarity, and impact**.
- Case Study Reports evaluated on **clarity, rarity, and contribution to clinical understanding**.
- All abstracts are peer-reviewed by category.
- Abstracts will not be re-classified once submitted.

Authors' Consent and Waiver of Claims

Completion of all required information in the online abstract submission system serves as an agreement. It certifies the ACMG abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that:

- Each abstract author agrees and certifies that they:
 - **have read all the rules and agrees to be bound by them,**
 - is responsible for submission of the abstract in accordance with the rules, and

- waives any and all claims against ACMG and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract Submission Requirements:

- The abstract must address scientific questions, detail clinical observations, and/or contain primary scientific data. We encourage authors to highlight why their abstract is novel or how it provides a unique contribution or perspective.
- Authors assign copyright of the abstract to ACMG upon submission, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.
- All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the [Declaration of Helsinki](#) of the World Medical Association.
- Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. The reviewers will have this information available during their evaluation.
- No revisions can be made after the abstract submission deadline (November 14, 2025).
- The presentation at the annual meeting must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must reflect the submitted abstract.
- Abstracts should be written in clear and concise English to ensure that reviewers can focus solely on the scientific merits of the submission. For authors whose primary language is not English, we encourage having abstracts checked for grammar and spelling before submission.
- It is expected that the presenting author will have a sufficient command of English to deliver the presentation and respond to questions. If this is not the case, authors are encouraged to choose a poster presentation as their preference.
- Abstracts can be submitted if:
 - It is unpublished and original
 - Accepted for publication but not yet published
 - Encore presentations are allowed, only if material was previously presented at non-genetics meeting within the last 6 – 12 months.

Acceptance/Rejection Notification

- Notification regarding acceptance or rejection of abstracts will be sent to the submitting author on December 10, 2025, by email; consequently, an accurate personal email address is critical. If your abstract is accepted, the email will specify whether it is accepted as Platform or Poster presentation.
- Once the abstracts are accepted, they will be formatted for publication in an online supplement to *Genetics in Medicine Open* (<https://www.gimopen.org/>). Therefore, abstract authors should

carefully review their abstract before submission to ensure that all authors and their affiliations are listed correctly.

- The decision of the ACMG Program Committee regarding acceptance and presentation of abstracts is final.

Abstract Withdrawal

- Once an abstract is accepted, a written request to withdraw must be submitted no later than February 6, 2026, to Education@ACMG.net if the first author decides to withdraw the abstract for any reason. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis.
- ACMG reserves the right to withdraw abstracts that are in violation of the College's policies and guidelines, or *GIM's* formatting guidelines, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
- For any abstract submitters with non-withdrawn abstracts who do not fulfill their professional commitment of presenting at the meeting, ACMG reserves the right to consider this information in the selection of abstracts for presentation in the future.

ACMG Annual Meeting Embargo Policy

All meeting attendees, presenters, authors, the media, exhibitors, institutions, industry and all other organizations and individuals are required to abide by the ACMG Annual Meeting Embargo Policy.

All abstracts, posters and oral (platform) scientific presentations are under strict embargo once ACMG has notified a presenter of their abstract's acceptance.

An embargo means that information from any abstract, poster or presentation is confidential and may not be announced, publicized, or disseminated before the embargo lift dates and times, as detailed below. The purpose of the ACMG Embargo Policy below is to protect the scientific integrity of all content presented at the ACMG Annual Clinical Genetics meeting and to ensure publicity is not released prematurely.

All ACMG Annual Clinical Genetics Meeting content to be presented or published is embargoed until the time of an actual conference presentation, ACMG has updated its guidelines to reflect the current e-publishing and online environment. The Embargo Policy below provides more details regarding the types of content that are embargoed.

The ACMG Embargo Policy is based on trust. Violation of the ACMG Embargo Policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate may be taken. Media who violate the Embargo Policy may lose their ACMG press credentials and be removed from the list to receive embargoed copies of ACMG news releases.

Specific Embargo Dates and Times:

Abstracts – Embargoed until posted on the ACMG Meeting website

Accepted abstracts will be made available online in advance of the ACMG Annual Clinical Genetics Meeting and will also be published in a special online supplement to our official open access journal, *Genetics in Medicine Open*. The information contained in abstracts is embargoed ***until the abstracts are available and published online***. Information contained in abstracts may not be released in any format, including preprints, until the abstracts appear online.

ACMG continues to require that any information that goes beyond that contained in the submitted abstract is under embargo until the times specified below.

Posters – Embargoed until Wednesday, March 11, 2026, at 5:00 pm ET

For abstracts selected for posters, the embargo will lift ***when the eposters are published via ACMG***.

Oral (Platform) Scientific Presentations – Presentations Embargoed until start of live session

The embargo for all scientific presentations will lift at the start time of the session in which the live presentation is being made. Interviews with presenters as well as any information to be presented for the first time at the ACMG Annual Meeting, are embargoed ***until the time of the live presentation in which the paper will be given***.

For questions about the ACMG embargo policy, email education@acmg.net.

Abstract Submission Policies

Financial Disclosure Policy (will be completed by **Platform or Case Challenge Presenter**)

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.

**Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*

Standard to Prevent Commercial Bias and Marketing in Accredited Continuing Education

ACCME requirements are designed to ensure that CME activities are independent and free of commercial bias.

Accredited continuing education must protect learners from commercial bias and marketing.

The accredited provider must ensure that all decisions related to the planning, faculty selection, delivery, and evaluation of accredited education are made without any influence or involvement from the owners and employees of an ineligible company.

Accredited education must be free of marketing or sales of products or services. Faculty must not actively promote or sell products or services that serve their professional or financial interests during accredited education.

The accredited provider must not share the names or contact information of learners with any ineligible company or its agents without the explicit consent of the individual learner.

Platform or Case Challenge Presenters' Responsibility Regarding Financial Disclosure (ACCME Compliance)

- The presenting author for a platform presentation will be contacted and must complete the online financial disclosure form and additional items pertaining to their presentation and participation.
- Employees of ACCME defined ineligible company may not present an accredited platform presentation.
- The content of the information with which you are involved will promote quality in health care or advances in science and will not promote a specific proprietary or commercial interest. Content for this publication will be well-balanced and unbiased.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

- [Financial Disclosures and Mitigation Procedure](#)
- [ACMG Content Validation Policy](#)
- [ACMG Content Branding Policy](#)

Scientific Abstract Awards

David L. Rimoin Inspiring Excellence Award

The ACMG Foundation for Genetic and Genomic Medicine will award the David L. Rimoin Inspiring Excellence Award given to a selected student, trainee, or junior faculty ACMG member whose abstract submission in **clinical genetics and therapeutics category** is chosen as a platform presentation during the 2026 ACMG Annual Clinical Genetics Meeting. In recognition of their selected presentation, the Rimoin Fund will provide a **cash award of \$1,000 and registration, travel and 3 nights' accommodations to attend the meeting.**

How to be considered for the David L. Rimoin Inspiring Excellence Award:

- All geneticists-in-training, who are both first author and presenter of the abstract in clinical genetics and therapeutics category, are considered for an Abstract Award. Therefore, you must identify as a geneticist-in-training and then select the appropriate training category (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) in the online abstract submission system.

- As a geneticist-in-training, you are required to submit a letter from the senior investigator overseeing your research confirming your status as a geneticist-in-training. The deadline for receipt of the geneticist-in-training letter is, therefore, November 14, 2025. There will be no exceptions.
- Your letter must be typed on your institution's letterhead, signed by the senior investigator, saved in PDF format, and uploaded to the online abstract submission system.
- Please include the following items in your letter: Author name (this is the geneticist-in-training who is the presenting/contact author); Confirmation of your status as a geneticist-in-training
 - Abstract Award recipients will be notified if they are to receive an award the week of December 15, 2025. You must register and attend the meeting and present your abstract to receive your award.

Eligible candidates interested in entering the competition will indicate so during the abstract submission process.

The ACMG Foundation for Genetic and Genomic Medicine Early Career Travel Award

The ACMG Foundation for Genetic and Genomic Medicine will award the Early Career Travel Award to a selected ACMG Member geneticist-in-training (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow), who is both first author and presenter of the abstract whose abstract submission is chosen as a platform presentation at the 2026 Meeting. This travel award includes complimentary registration and provides up to **\$2,600** to cover travel and hotel costs.

How to be considered for the Early Career Travel Award:

- All ACMG Member geneticists-in-training, who are both first author and presenter of the abstract will have the opportunity to compete for this Abstract Award. Therefore, you must identify as a geneticist-in-training and then select the appropriate training category (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) in the online abstract submission system.
- As a geneticist-in-training, you are required to submit a letter from the senior investigator overseeing your research confirming your status as a geneticist-in-training. The deadline for receipt of the geneticist-in-training letter is, therefore, November 14, 2025. There will be no exceptions.
- Your letter must be typed on your institution's letterhead, signed by the senior investigator, saved in PDF format, and uploaded to the online abstract submission system.
- Please include the following items in your letter: Author name (this is the geneticist-in-training who is the presenting/contact author); Confirmation of your status as a geneticist-in-training
 - Abstract Award recipients will be notified if they are to receive an award the week of December 15, 2025. You must register and attend the meeting and present your abstract to receive your award.

Eligible candidates interested in entering the competition will indicate so during the abstract submission process.

The ACMG Foundation for Genetic and Genomic Medicine Genetic Counselor Abstract Award

The ACMG Foundation for Genetic and Genomic Medicine will be giving the Genetic Counselor Abstract Award to the first author of the highest rated genetic counselor-authored abstract submission for the scientific program at the 2026 ACMG Annual Clinical Genetics Meeting.

How to be considered for the ACMG Foundation Genetic Counselor Abstract Award

- The ACMG Genetic Counselor Award will be presented to the recipient at the 2026 ACMG Annual Clinical Genetics Meeting. In recognition of their selected presentation, a **\$1000 cash** award will be given to the recipient. The recipient will also receive an invitation to the ACMG Foundation donor reception at that year's annual meeting.
- Applicants must be certified- or board-eligible Genetic Counselor or genetic counseling graduate student enrolled in an accredited genetic counseling training program and do not have to be an ACMG member.
- Eligible candidates interested in entering the competition will indicate so during the abstract submission process.

Embargo and Policies

- Abstracts embargoed until posted online.
- Posters embargoed until **March 11, 2026, 5:00 p.m. ET.**
- Platform presentations embargoed until the start of the live session.
- ACMG embargo policy applies to all attendees, presenters, and media.

(retain full embargo, disclosure, terminology, and submission policies.)

How to Submit

- Online submission opens **October 1, 2025** via www.acmgmeeting.net.
- Deadline: **Friday, November 14, 2025, at 11:59 p.m. PT.**
- Abstracts not submitted through the online system will not be accepted.
- Technical support available M–F, 9:00 a.m.–5:00 p.m. CT.

Preparing an Abstract for Submission

Please read the formatting guidelines before submission. Abstracts that are incorrectly formatted may be returned prior to review.

Contact Information

- Your name, degree, institution, address, phone number, and email address must be provided. As the corresponding author, you will receive all future correspondence from ACMG.
- The submitting author should be the first author (presenter) of the abstract, unless otherwise noted during submission.

Co-Authors

- Names of co-authors and institutions must be provided. **Changes will not be made to the spelling of authors' names after the submission deadline**; please proof your co-authors' names carefully.

Copyright Policy

- All authors must assign copyright of the abstract to ACMG, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright).

Abstract Title

- The abstract title should be brief and clearly indicate the nature of the abstract. You may use up to 20 words.
- The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase "to" when used as an infinitive. See examples [here](#).
- Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as aCGH.
- Do not put a period at the end of the title.
- For example: Cancer Genetics: Translation of New Concepts to Clinical Care

Use of Product Names

- Non-proprietary (generic/scientific) names should be used and should be lowercase.
- If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ACMG reserves the right to replace proprietary names with generic names to adhere to this policy.

Abbreviations

- Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Terminology

Please refer to [Terminology in the *Genetics in Medicine* instructions to authors for detailed information](#).

ACMG has preferred terminology that **must** be followed. We also require that all sequence variants follow HGVS nomenclature and that variants are classified as per the ACMG/AMP Guidelines.

Terminology Check

Whole genome sequencing or whole-exome sequencing

- The preferred terminology is Genome sequencing (GS) or Exome sequencing (ES)

Invasive/NIPS/NIPT

We note the use of the terminology "noninvasive prenatal screening" and/or its acronym. In accordance with the ACMG, please use the term "prenatal cell-free DNA screening" or prenatal screening by cell free DNA to describe this screening test. The term "cell-free DNA" can be abbreviated as cfDNA; no other abbreviated forms of this term are permitted. When using the term "cell-free DNA" to describe its application in settings other than prenatal (such as in oncology), after being defined in the manuscript as cell-free DNA, the abbreviation cfDNA should be used.

Incidental

- Incidental findings when results are not being intentionally sought though they may be anticipated (known to be potentially associated with the test) or unanticipated (not typically associated)
- Secondary findings when results are actively sought but not the primary reason for testing

Mutation and Carrier

GIM has preferred usage for certain terms

(<https://www.gimjournal.org/content/authorinfo#terminology>). We ask you to check your article to ensure those terms are used correctly. In particular, please note the following preferred terminology:

Mutation

- variant instead of mutation
- pathogenic variant to denote a disease-causing variant
(Use of frameshift mutation, mutational, mutation hotspot, mutation rate is permitted)

Carrier

- heterozygote (rather than carrier) when referring to a person's genotype/genetic test result. Explanation: The usage is intended to deal with the issue that "heterozygote" describes the presence of a variant, regardless of classification, but "carrier" typically implies that the variant is disease-causing. Preferred terminology is "heterozygous for a pathogenic variant". Carrier status, Carrier frequency, Carrier testing, Carrier result, and carrier screening are all permissible.

Caucasian, etc.

We note the use of the term "Caucasian" to describe one of the studied populations. For race, ethnicity, and genetic ancestry terms, GIM Open follows the "[Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals published in JAMA](https://jamanetwork.com/journals/jama/fullarticle/2783090)" (<https://jamanetwork.com/journals/jama/fullarticle/2783090>) and the copy editing guidelines in the AMA Style Guide (<https://doi.org/10.1093/jama/9780190246556.003.0011>). Specifically, we do not allow the use of the term "Caucasian" unless it refers to people from the Caucasus region.

VUSs

Please use the acronym VUS (not VUSs) as VUS can be plural or singular (variants of uncertain significance or variant of uncertain significance)

Unknown vs Uncertain

- Use the term "variant(s) of uncertain significance" instead of "variant(s) of unknown significance"

Subject

- When referring to persons included in research studies, 'participant' is preferred. A research 'participant' (preferred to subject'; see below) is a person who undergoes an intervention as part of a scientific investigation. A 'patient' is a person under medical care and 'patient' is not expected to be widely used in GIM articles; rather 'participant' or 'person' are generally preferred. 'Subject' (as in study/research subject) is impersonal, perhaps derogatory, suggesting a subservient role and should not be used.

Primacy

- Claims of primacy and novelty are discouraged, e.g., *for the first time*.

Electronic Signature

Completion of all required information in the online abstract submission system serves as an agreement. It certifies the ACMG abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that:

1. All authors approve of submitting this work for presentation and publication;
2. The author(s) transfer(s) all copyright ownership of the named abstract to the American College of Medical Genetics and Genomics (except when one or more authors are U.S. Government employees);
3. Submitter is acting on behalf of authors and has read the ACMG Conflict-of-Interest Policy and has acted in accordance with that policy;
4. The author(s) agree(s) to materially confine the presentation to information in the abstract, if accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session;
5. The presenting author will be available to present the abstract if selected for the program. The author(s) will immediately notify ACMG if the first author is not the presenting author. Presenting author will be required to complete presenter documents including financial disclosure.

Contact Information

Send related correspondence and questions regarding abstract submissions or notifications to Education@ACMG.net.

ACMG Annual Meeting Registration and Housing www.acmgmeeting.net

- **Please note that submitting an abstract does not register you for the ACMG annual meeting.**
- Platform moderators, co-moderators, and presenters are not eligible to receive entitlements.

To register, you must complete and return an Attendee Registration Form, or register online through the ACMG Meeting website (www.acmgmeeting.net).